On-Demand Presentations and Slides

Urothelial Cancer Preceptorship

Release date: 25-10-2022

Expiration date: 24-10-2023

The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted and antibody-drug conjugates adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the ‘Urothelial Cancer Preceptorship’, in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease. View didactic presentations from the program, which aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides are also available to download.

Based on the Preceptorship held on 21 and 22 July, 2022.


Enrique Grande, MD, MSc, PhD

Enrique Grande, MD, MSc, PhD | Chair

MD Anderson Cancer Center Madrid

Madrid, Spain

Enrique Grande is the current Director of the Medical Oncology Program at the MD Anderson Cancer Center Madrid. Dr. Grande is focused on the research into genitourinary tumors and is actively involved in collaborating on the development of the Translational Research and Early Drug Development Unit. Dr. Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Center (CNIO). A published author of more than 200 manuscripts in peer-reviewed journals, Dr. Grande is also the founder of the Spanish group for research on orphan and uncommon tumors (GETHI). Dr. Grande is the editor of several international journals and has been the editor of a range of books related to oncology. Dr. Grande has participated in the most recent trials in the field of genitourinary and neuroendocrine tumors that led to the approval of the new drugs we now have available.

Francisco X. Real, MD, PhD

Francisco X. Real, MD, PhD

National Cancer Research Center

Madrid, Spain

Francisco X. Real (Paco) has been Professor of Cell Biology at Universitat Pompeu Fabra, Barcelona, Spain, since 2004, and he has also worked at Spanish National Cancer Research Center (CNIO), Madrid, Spain, since 2007. He obtained his MD from the Universitat Autònoma de Barcelona in 1980 and his PhD in 1986. He trained in Medical Oncology at Memorial Hospital in New York where he was a Staff Physician from 1986 to 1988. He carried out his doctoral and postdoctoral work in the laboratory of Lloyd J. Old at Memorial Sloan-Kettering Cancer Center. His work focused on the development of immunological strategies for the treatment of melanoma and epithelial cancers. In 1988, he joined the Institut Municipal d'Investigació Mèdica, Barcelona, where he focused on the cell and molecular biology of epithelial cancers. He was also involved in setting up the Biomedical Sciences studies at Universitat Pompeu Fabra.

At CNIO, Professor Real's group has made significant contributions to the molecular mechanisms involved in pancreatic cancer and in pancreatitis and the molecular pathology and epidemiology of bladder and pancreas cancer. His work combines the use of patient samples, cultured cells, and genetically modified mice, giving a similar relevance to all of them. One important aim of the group’s work is to bring the fundamental knowledge generated in the laboratory to an improved understanding of disease and to develop improved strategies for prevention, early diagnosis, and treatment of pancreatic and bladder cancer.

Professor Real has published more than 300 original papers and his work has been published in Nature, Nature Genetics, Nature Cell Biology, Nature Communications, Nature Reviews Cancer, Gut, Gastroenterology, PNAS, JNCI, J Clin Invest, N Engl J Med, and Lancet, among others. He has received more than 29,000 citations (Google Scholar); his H index is 96. He is a member of the Scientific Advisory Board of several institutions including the Discovery Research Committee of Cancer Research UK (London), Centre de Recherche des Cordeliers (Paris), CARPEM (Paris), Pancreatic Cancer Research UK (London), and Fonds National de la Recherche Scientifique (Brussels). He is an Associate Editor of Gut and Bladder Cancer. In 2015, he was President of the European Pancreatic Club.

Fernando Lista, MD, PhD

Fernando Lista, MD, PhD

MD Anderson Cancer Center Madrid

Madrid, Spain

Fernando Lista Mateos has been the Chief of the Endourology Section in the Department of Urology and Urologic Surgery at the MD Anderson Cancer Center (MDACC) Madrid, Spain, since 2014, and has notable experience in oncologic laparoscopic and robotic procedures (e.g. radical prostatectomy, nephrectomy and radical cystectomy). In addition, he is a member of the Robotic Surgery Team at MDACC Madrid, with experience in percutaneous retrograde intrarenal surgery (RIRS), HistoScanning perineal prostate biopsy, and focal therapy for prostate cancer.

Dr. Lista completed his Bachelor of Medicine at the Universidad Autonoma of Madrid in 2008 and specialized in Urology via MIR in 2014. He has since been certified as a DaVinci Console Surgeon and received a PhD in health sciences. He is a member of the Official College of Physicians of Madrid and a Fellow of the European School of Urology.

Dr. Lista is a member of several professional bodies and a board member and reviewer for several prominent scientific journals. In addition, he has been named as Investigator on several study protocols, has given many presentations at national and international conferences, and has published over 20 articles in scientific journals.

  • What an oncologist needs to know about the pathology and biology of urothelial carcinomas | Francisco X. Real, MD, PhD

  • Challenges in non-muscle-invasive urothelial carcinomas: From guidelines to new clinical trials | Fernando Lista, MD, PhD

  • Defining BCG-refractoriness in clinical practice: Case discussion | Fernando Lista, MD, PhD

  • Setting the scene for systemic perioperative treatment of muscle-invasive bladder cancer: The battle between neoadjuvant vs. adjuvant approaches | Enrique Grande, MD, MSc, PhD

  • Caveats to the use of immunotherapy in the adjuvant setting | Enrique Grande, MD, MSc, PhD

  • Summarizing 4 decades of systemic treatment for urothelial cancer patients in 50 minutes | Enrique Grande, MD, MSc, PhD

  • New drugs and mechanisms of action under development in urothelial carcinomas | Enrique Grande, MD, MSc, PhD

This activity is designed for medical oncologists involved or interested in the management of urothelial carcinoma.

The aim of this educational activity is for participants to:


  • Develop a greater awareness of the different molecular and pathologic subtypes of urothelial cancers and the role of prognostic and predictive biomarkers in patient management
  • Appreciate the current and evolving treatment options for non-muscle-invasive bladder cancer (NMIBC)
  • Establish confidence and expertise in the selection and timing of systemic treatment options throughout the clinical course of locally advanced and metastatic urothelial cancers
  • Improve understanding of the important research questions in urothelial cancer and how these might be addressed

This educational activity is provided by ACE Oncology.

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:


Enrique Grande has served as an advisor or consultant for Advanced Accelerator Applications, AMGEN, Angelini, Astellas, AstraZeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Dr. Reddy’s, Eisai, Esteve, Eusa Pharma, Genetracer, GSK, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, Tecnofarma, Thermo Fisher Scientific, and Zodiac. He has served as a speaker or a member of a speakers bureau for Advanced Accelerator Applications, Astellas, AstraZeneca, Bristol Myers Squibb, Dr. Reddy’s, Eisai, Esteve, Eusa Pharma, IPSEN, Janssen, Lilly, Merck KGaA, MSD, Pfizer, Roche, Sanofi-Genzyme, Tecnofarma, and Zodiac. He has also received grants for clinical research from Astellas, AstraZeneca, IPSEN, Lexicon, Merck KGaA, MTEM/Threshold/Tersera, Nanostring Technologies, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


Francisco X. Real has received grants for clinical research from VCN Biosciences and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


Fernando Lista has served as a speaker or a member of a speakers bureau for AstraZeneca, Bristol Myers Squibb, and Pfizer. He has also received grants for clinical research from MD Anderson Cancer Center. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


The employees of ACE Oncology have disclosed no relevant financial relationships.


ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Start Activity